Status:
ENROLLING_BY_INVITATION
Investigating the Role of Genetics in Disease Predisposition
Lead Sponsor:
The Wellcome Sanger Institute
Conditions:
Predisposition, Genetic
Cancer
Eligibility:
All Genders
Brief Summary
Gametogenesis is the production of sperm and eggs; it takes place through the process of meiosis. Gametogenesis is subject to the acquisition of mutations as with other processes in the body. Many of ...
Detailed Description
Predisposition to rare disorders and cancers can arise due to mutations (changes in DNA) of sperm cells from father and/or eggs from mother. De novo mutations are genetic alterations that are present ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Minimum of child affected with cancer pre-disposition syndromes and their father
- Additional family members of consented father and child duos (Mother, same parent siblings, Maternal/Paternal Aunts, uncles and grandparents of affected child)
- Reproductive tissue samples from both men and women affected by cancer collected with consent for use in research.
- Reproductive tissue samples from both men and women unaffected by cancer collected with consent for use in research.
- Exclusion:
- Fathers who do not wish to donate a semen sample or are unable to will be excluded from the study, as will their families
- Fathers who have had a vasectomy will be excluded from the study as will their families
- Adults who do not have the capacity to consent for themselves will be excluded from the study.
- Families in which both parents do not have capacity to consent will also be excluded as they will be unable to give parental consent for their children's participation.
- In order to be eligible siblings must share the same two parents as the affected child, all other siblings will be excluded from the study.
- Male relatives in the extended family (Maternal/Paternal Aunts, uncles and grandparents of affected child) unwilling or unable to donate both a blood or saliva sample and a semen sample will be excluded from the study.
- Participants who do not have a good understanding of the English language will be excluded from the study.
Exclusion
Key Trial Info
Start Date :
June 20 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2027
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT06584994
Start Date
June 20 2021
End Date
March 1 2027
Last Update
September 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wellcome Sanger Institute
Cambridge, United Kingdom